• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2379-089X
    Volume 5, Issue 3
    News Letter
    Xiaoping Xie*
    As a postdoctoral fellow of The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, US, I mainly work on molecular mechanisms regulating T cell functions in inflammation, autoimmunity, and cancer immunity.
    Review Article
    Mark A. D'Andrea and G. Kesava Reddy*
    Cisplatin is a first generation chemotherapy agent whose anticancer activity was discovered through serendipity. The accidental discovery of its anticancer properties in the 1970s represents a major landmark in the history of successful anticancer agents. Cisplatin is an effective anticancer agent that has been successfully utilized in the treatment of a wide range of cancers including lung, head and neck, testicular, bladder, cervical, and ovarian cancers. Cisplatin exerts its cytotoxic effects by forming DNA adducts and subsequently inhibiting DNA replication. However, its dose-limiting adverse toxicity profile, the low biological availability and the development of resistance to cisplatin treatment in certain tumors has led to the development of other platinum (II) analog s such as carboplatin, oxaliplatin, etc., as potential anticancer drugs. Alternatively, to minimize the tumor resistance and improve its clinical effectiveness, cisplatin was combined successfully with other cytotoxic drugs. Currently, cisplatin combination regimens are the premier form of combination therapy for a variety of tumors including lung, head and neck, bladder, cervical, ovarian and other solid tumors. In this review article, we provide an overview of the current state of knowledge and clinical experience of cisplatin specifically highlighting its historical background, mechanism of action, development of tumor resistance and strategies to overcome its resistance in the treatment of cancer. In addition, we analyzed the current use of platinum-based combination therapies with novel cytotoxic drugs, and new targeted and immunotherapeutic agents in the treatment of non-small lung cancer.
  • JSciMed Central Blogs
  • JSciMed Central welcomes back astronaut Scott Kelly and cosmonaut Mikhail Kornienko.
    Readmore...

    Wonder Women Tech not only disrupted the traditional conference model but innovatively changed the way conferences should be held.
    Readmore...

    JSciMed Central Peer-reviewed Open Access Journals
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.